BridgeBio Oncology Therapeutics (BBOT) Non Operating Income (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Non Operating Income for 3 years, with the latest figure at $4.1 million in Q1 2026.

• Quarterly Non Operating Income rose 276.43% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (up 89.83% YoY) and the FY2025 annual result came in at $11.8 million, up 78.73% from the prior year.
• Non Operating Income fell to $4.1 million in Q1 2026 per BBOT's latest filing, from $4.6 million in the prior quarter.
• Over five years, Non Operating Income peaked at $4.6 million in Q4 2025 and troughed at $1.1 million in Q1 2025.
• A 3-year average of $2.7 million and a median of $2.3 million in 2024 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2025 and 2026: Non Operating Income fell 13.73% in 2025, then jumped 276.43% in 2026.
• Over 3 years, Non Operating Income stood at $2.2 million in 2024, then jumped by 110.36% to $4.6 million in 2025, then slipped by 11.67% to $4.1 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $4.1 million, $4.6 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.